Publications
Scientific Publications & Presentations
Explore data from our clinical programs across central nervous system disorders, including movement disorders and epilepsy, supported by our precision neuroscience approach.
| 2024 MDS Congress |
|---|
| Essential3: An Innovative Multi-Study Phase 3 Program to Evaluate the Efficacy and Safety of Ulixacaltamide |
| 2024 AAN Annual Meeting |
|---|
| Assessing Clinically Meaningful Improvement Associated with Ulixacaltamide Treatment in Adults with Essential Tremor on Concomitant Propranolol: Findings from Essential1 |
| 2023 IAPRD Meeting |
|---|
| Essential1: Results from a Phase 2 Trial Evaluating the Tolerability, Safety, and Efficacy of Ulixacaltamide in Adults with Essential Tremor |
| Ulixacaltamide Translational Findings in Movement Disorders |
|---|
| Translational Pharmacology of PRAX-944, a Novel T-Type Calcium Channel Blocker in Development for the Treatment of Essential Tremor |
| ET Claims Analysis in Advances in Therapy |
|---|
| The Hidden Burden of Disease and Treatment Experiences of Patients with Essential Tremor: A Retrospective Claims Data Analysis |
| TTCC Mechanistic Review in Annals of Clinical and Translational Neurology |
|---|
| T-type Calcium Channels as Therapeutic Targets in Essential Tremor and Parkinson's Disease |
| 2022 AES Annual Meeting and Behind the Seizure Scientific Exhibit |
|---|
| Disease Impact and Burden in Patients with SCN2A-Related Developmental and Epileptic Encephalopathy |
| A Novel Approach to Assess the Impact of Disease in Patients with SCN8A-Related Developmental and Epileptic Encephalopathy |
| 2021 AES Annual Meeting |
|---|
| Patient-guided Approaches to Drug Development in SCN8A-related Epilepsy: Insights from a Caregiver Survey of Feeding & Medication Formulation Priorities |
| 2024 EEC Meeting |
|---|
| Pharmacokinetics, Tolerability and Cardiac Safety for PRAX-628, a Precision Medicine Therapeutic Set to Initiate Registration Enabling Studies for Focal Onset Seizures |
| 2023 AAN Annual Meeting |
|---|
| PRAX-628: A Novel Sodium Channel Blocker with Greater Potency and Activity Dependence Compared to Standard of Care |
| 2023 Oligonucleotides for CNS Meeting |
|---|
| Leveraging Preclinical Models To Inform Clinical Trial Strategy in SCN2A Developmental and Epileptic Encephalopathy |
| 2022 AES Annual Meeting and Behind the Seizure Scientific Exhibit |
|---|
| Disease Impact and Burden in Patients with SCN2A-Related Developmental and Epileptic Encephalopathy |
| 2022 Drug Discovery for Ion Channels XXII Meeting |
|---|
| Using Dynamic Action Potential Clamp Modeling of NaV1.2 Variants to Support the Prediction of Clinical Phenotype in DEE |
| Elsunersen First-in-Human Case in Nature Medicine |
|---|
| Antisense Oligonucleotide Treatment in a Preterm Infant With Early-Onset SCN2A Developmental and Epileptic Encephalopathy |
| 2025 IEC Meeting |
|---|
| Establishing the Predictive Validity of Preclinical Seizure Models in Generalized Epilepsies: An Extension of the Praxis Analysis of Concordance Framework |
| 2024 EEC Meeting |
|---|
| A Novel Method to Define an EEG Composite for the Detection of Drug Effects of Next Generation Small Molecules for Epilepsy |
| 2023 SYNGAP1 Conference |
|---|
| Progress Toward the Discovery of an ASO for Therapeutic Upregulation of SYNGAP1 |
| 2021 AES Annual Meeting |
|---|
| PRX-2904 is a Small Molecule Selective Inhibitor of KNa1.1 (KCNT1) that Reverses the ECoG Phenotype of a KCNT1 Gain-of-Function Mouse Model |
| PAC-FOS in Epilepsia |
|---|
| PAC-FOS: A Novel Translational Concordance Framework Identifies Preclinical Seizure Models with Highest Predictive Validity for Clinical Focal Onset Seizures |
| PRX-2904 Chemistry in ACS Medicinal Chemistry Letters |
|---|
| Discovery of the First Orally Available, Selective KNa1.1 Inhibitor: In Vitro and In Vivo Activity of an Oxadiazole Series |